Genmab A/S (NASDAQ:GMAB - Get Free Report) has received a consensus rating of "Moderate Buy" from the nine ratings firms that are currently covering the stock, Marketbeat reports. Three analysts have rated the stock with a hold recommendation and six have given a buy recommendation to the company. The average twelve-month price target among brokers that have updated their coverage on the stock in the last year is $45.20.
A number of brokerages recently commented on GMAB. HC Wainwright reaffirmed a "buy" rating and set a $50.00 price objective on shares of Genmab A/S in a research report on Thursday, January 23rd. BMO Capital Markets restated an "outperform" rating and issued a $48.00 price target (up from $46.00) on shares of Genmab A/S in a research report on Friday, November 8th. Finally, Sanford C. Bernstein upgraded Genmab A/S from a "strong sell" rating to a "hold" rating in a research note on Friday, December 20th.
Get Our Latest Research Report on Genmab A/S
Institutional Trading of Genmab A/S
Large investors have recently made changes to their positions in the company. EverSource Wealth Advisors LLC grew its stake in Genmab A/S by 295.3% in the fourth quarter. EverSource Wealth Advisors LLC now owns 1,257 shares of the company's stock valued at $26,000 after acquiring an additional 939 shares during the period. Lindbrook Capital LLC grew its position in shares of Genmab A/S by 105.4% in the 4th quarter. Lindbrook Capital LLC now owns 1,851 shares of the company's stock valued at $39,000 after purchasing an additional 950 shares during the period. GAMMA Investing LLC increased its stake in Genmab A/S by 96.6% during the 4th quarter. GAMMA Investing LLC now owns 2,139 shares of the company's stock worth $45,000 after purchasing an additional 1,051 shares in the last quarter. Cromwell Holdings LLC increased its stake in Genmab A/S by 656.8% during the 4th quarter. Cromwell Holdings LLC now owns 2,876 shares of the company's stock worth $60,000 after purchasing an additional 2,496 shares in the last quarter. Finally, R Squared Ltd acquired a new stake in Genmab A/S during the 4th quarter worth approximately $93,000. Institutional investors own 7.07% of the company's stock.
Genmab A/S Stock Up 1.1 %
Shares of NASDAQ GMAB traded up $0.20 during mid-day trading on Friday, hitting $18.89. 1,338,229 shares of the company traded hands, compared to its average volume of 1,537,668. The business has a 50 day moving average of $20.78 and a two-hundred day moving average of $23.30. The stock has a market capitalization of $12.50 billion, a price-to-earnings ratio of 18.34, a PEG ratio of 0.54 and a beta of 0.96. Genmab A/S has a 1 year low of $18.64 and a 1 year high of $31.88.
Genmab A/S Company Profile
(
Get Free ReportGenmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.
Further Reading
Before you consider Genmab A/S, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Genmab A/S wasn't on the list.
While Genmab A/S currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Thinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
